case_images: PMC7275238_01
case_images: Breast MRI. Smooth circumferential thickening of the right implant fibrous capsule noted with diffuse progressive enhancement.
case_images: CRIPA2020-2157485.001.jpg
case_images: PMC7275238_01_CRIPA2020-2157485.001.jpg
case_images: fig1
case_images: The MRI showed smooth circumferential thickening of the right implant fibrous capsule with diffuse progressive enhancement (Figure 1).
case_images: (a, b) Right breast capsule macroscopic appearance. Initial (malignant) capsulectomy specimen showing thickened, "velvety" appearance. (c-f) Right breast peri-implant capsule with exudate, microscopic appearance. Malignant lymphoid cells within the fibrinous exudate show large, irregular nuclei with prominent nucleoli.
case_images: CRIPA2020-2157485.002.jpg
case_images: PMC7275238_01_CRIPA2020-2157485.002.jpg
case_images: fig2
case_images: Marked thickening, fibrinous debris, and a "velvety" appearance of the capsular surface were noted (Figures 2(a) and 2(b)). Histological analysis showed that there were atypical lymphoid cells in the fibrinous exudate from around the implant (Figures 2(c)-2(f)).
case_images: (a-f) Immunohistochemical staining of the right breast peri-implant capsule with exudate. The malignant lymphoid cells stain positively for CD30 and are negative for CD3, CD20, CD68, and AE1/3.
case_images: CRIPA2020-2157485.003.jpg
case_images: PMC7275238_01_CRIPA2020-2157485.003.jpg
case_images: fig3
case_images: Alk, CD2, CD20, CD3, CD4, CD5, CD7, CD8, and Granzyme B were all negative (Figures 3(a)-3(f)).
case_images: (a, b) Reresection of the right breast peri-implant capsule with exudate, microscopic appearance. Marked synovial metaplasia of the capsule and focal infiltration by small lymphocytes. No evidence of residual malignancy.
case_images: CRIPA2020-2157485.004.jpg
case_images: PMC7275238_01_CRIPA2020-2157485.004.jpg
case_images: fig4
case_images: Histological sections showed marked synovial metaplasia of the capsule and focal infiltration by small lymphocytes (Figures 4(a) and 4(b)).